[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595545":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":29,"responsibleParty":44,"collaborators":46,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":18,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":18,"studyType":64,"phases":65,"briefSummary":55,"conditions":67,"keywords":70,"overallStatus":32,"whyStopped":18,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Applied Biology, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Phenylephrine","EXPERIMENTAL","Topical Phenylephrine",[13],"Device: Phenylephrine",[15],{"type":16,"name":9,"description":11,"armGroupLabels":17,"otherNames":18},"DEVICE",[9],null,[20],{"name":21,"affiliation":22,"role":23},"Andy Goren, MD","University of Rome G. Marconi","STUDY_DIRECTOR",[25],{"name":21,"role":26,"phone":27,"phoneExt":18,"email":28},"CONTACT","16507040850","clinicalstudies@appliedbiology.com",[30],{"facility":31,"status":32,"city":33,"state":18,"zip":18,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"University of Rome (\"G. Marconi\")","RECRUITING","Rome","Italy","IT",{"type":37,"coordinates":38},"Point",[39,40],12.51133,41.89193,{"lat":40,"lon":39},[43],{"name":21,"role":26,"phone":27,"phoneExt":18,"email":28},{"type":45,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[47,49],{"name":48,"class":6},"Daniel Alain, Inc.",{"name":50,"class":6},"Follea International Limited","100595545","early-phase-1-pharmacokinetic-study-of-topical-phenylephrine-100595545",false,"NCT07033845","Pharmacokinetic Study of Topical Phenylephrine","Inclusion Criteria:\n\n* Healthy females, age 18-55\n* BMI: 18-30 kg\u002Fm²\n* Fitzpatrick Skin Types I-IV (to standardize absorption risk)\n* Scalp free from irritation, dermatologic disease, or damage\n* Able to refrain from using other topical scalp products\n\nExclusion Criteria:\n\n* History of cardiovascular disease, hypertension, or arrhythmia\n* Scalp infections, wounds, or significant hair loss\n* Recent use of medications that interfere with CYP enzymes or adrenergic systems\n* Known sensitivity to phenylephrine or ethanol\n* Positive drug screen or abnormal ECG at screening",true,"FEMALE","18 Years","55 Years",{"count":62,"type":63},24,"ESTIMATED","INTERVENTIONAL",[66],"EARLY_PHASE1",[68,69],"Chemotherapy Induced Alopecia","Chemotherapy Side Effects",[68,71],"Chemotherapy Alopecia","2025-09-30",{"date":74,"type":75},"2025-10-03","ACTUAL",{"date":77,"type":75},"2025-06-30",{"date":79,"type":63},"2025-12-28",{"name":5,"class":6},1]